Scoring of outcomes considered relevant by the World Health Organization convened guideline development group for the evidence review for the 2020 update on multidrug/rifampicin-resistant tuberculosis (TB) treatment
| Outcomes (as outlined in the scoping proposal) | Rating |
| Survival (or death) | 8.33 |
| Relapse-free cure | 8.22 |
| Bacteriological cure by end of treatment | 8.19 |
| Successful completion of treatment (or lack of successful completion) | 7.96 |
| Treatment failure or relapse | 7.93 |
| Adherence to treatment (or treatment interruption due to nonadherence) | 7.48 |
| Acquisition (amplification) of drug resistance | 7.33 |
| Adverse events from anti-TB medicines | 7.19 |
Relative importance was rated on an incremental scale, as follows. 1–3 points: not important for making recommendations; 4–6 points: important, but not critical for making recommendations; 7–9 points: critical for making recommendations on the evaluated interventions.